AIM ImmunoTech Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from AIM ImmunoTech Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, equals 29% of its market value (net debt). Lower than 88% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 538% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-31.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 65% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 38%
Sales fell 38% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-38% / -86%In 3 years sales changed by -38% while total assets changed by -86%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-3.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 62% of Healthcare companies in United States.
Cash Cushion Ratio
−29%Debt, after subtracting cash, equals 29% of its market value (net debt).
Lower than 88% of Healthcare companies in United States.
Tangible Assets Ratio
71%Of every $100 the company owns, $71 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 60% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
AIM ImmunoTech Inc. made a loss over the last year. AIM ImmunoTech Inc. owes $0.75 for every $1 it owns. AIM ImmunoTech Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAIM ImmunoTech Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.02The share price is 3.02 times AIM ImmunoTech Inc.'s book value per share, higher than 56% of Healthcare companies in United States.
Market cap
$6 MThe total market value of all of AIM ImmunoTech Inc.'s shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat AIM ImmunoTech Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$0.05Net worth divided by the number of shares. The share price of $0.16 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
-2382.3%AIM ImmunoTech Inc. lost 2382.3% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
0.75×AIM ImmunoTech Inc. owes $0.75 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Dividend yield
NoneAIM ImmunoTech Inc. does not currently pay a dividend.
Revenue growth
-48%Revenue fell 48% in the year to Dec 2025, and shrank 15% a year on average over 3 years.
Profit growth
LossAIM ImmunoTech Inc. made a loss in each of the last two years.
Profit margin
-15861.4%AIM ImmunoTech Inc. lost $15861 for every $100 of revenue.
Interest cover
Not coveredAIM ImmunoTech Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtAIM ImmunoTech Inc. had $2 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For AIM ImmunoTech Inc.: $6 M ÷ $2 M (31 Mar 2026) = 3.0.
What is AIM ImmunoTech Inc.'s return on equity?
AIM ImmunoTech Inc. lost 2382.3% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does AIM ImmunoTech Inc. owe compared with what it owns?
AIM ImmunoTech Inc. owes $0.75 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Does AIM ImmunoTech Inc. pay a dividend?
No. AIM ImmunoTech Inc. does not currently pay a dividend.
Is AIM ImmunoTech Inc.'s revenue growing?
Revenue fell 48% in the year to Dec 2025, and shrank 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.